Transforming growth factor (TGF)-b is an important paracrine factor in tumorigenesis. Ligand binding of the type I and II TGF-b receptors initiate downstream signaling. The role of stromal TGF-b signaling in prostate cancer progression is unknown. In mice, the conditional stromal knockout of the TGF-b type II receptor expression (Tgfbr2 fspKO ) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months. Clinically, we observed a loss of TGF-b receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n ¼ 140, P-value o0.0001). To investigate the mechanism of paracrine TGF-b signaling in prostate cancer progression, we compared the effect of the prostatic stromal cells from Tgfbr2 fspKO and floxed TGF-b type II receptor Tgfbr2 floxE2/floxE2 mice on LNCaP human prostate cancer cells in vitro and tissue recombination xenografts. Induction of LNCaP cell proliferation and tumorigenesis was observed by Tgfbr2 fspKO prostate stroma as a result of elevated Wnt3a expression. Neutralizing antibodies to Wnt3a reversed LNCaP tumorigenesis. The TGF-b inhibition of Wnt3a expression was in part through the suppression of Stat3 activity on the Wnt3a promoter. In conclusion, the frequent loss of stromal TGF-b type II receptor expression in human prostate cancer can relieve the paracrine suppression of Wnt3a expression.
Introduction
Prostate cancer is the second leading cause of cancerrelated death in men in the United States. The understanding of stromal-epithelial interactions in the prostate will help determine the etiology of prostate cancer progression. Many factors including transforming growth factor (TGF)-b and Wnt signaling molecules are found to be mutated or deregulated in prostate cancer. Conventionally, TGF-b plays a tumor suppressive role in normal and preneoplastic epithelia, yet paradoxically can promote motility and resistance to cell death in transformed epithelia (Roberts and Wakefield, 2003; Bierie and Moses, 2006; Biswas et al., 2007) . Further data have emerged that TGF-b also has additional roles in the tumor microenvironment born out by mouse models with conditional ablation of TGFb signaling in a subset of stromal fibroblasts (Bhowmick et al., 2004a, b) . These studies suggest that TGF-b can be a paracrine tumor suppressor, as the stromal loss of TGF-b responsiveness initiated prostatic intraepithelial neoplasia (PIN) and squamous cell carcinoma in the forestomach (Bhowmick et al., 2004a) . In contrast, Wnt ligands are long known oncogenes (Nusse and Varmus, 1982; Nusse et al., 1984 Nusse et al., , 1991 . Canonical Wnt signaling, through b-catenin stabilization, has been of specific interest in cancer biology as a regulator of cell proliferation, adhesion, survival, movement and polarity. Together, the TGF-b and Wnt pathways have both opposite and synergistic roles in cancer progression with evidence of cross talk in cytoplasmic signaling (Nishita et al., 2000; Labbe et al., 2007) .
TGF-b signaling involves the binding of the ligand isoforms, TGF-b 1, 2 and 3 to the extracellular domain of the TGF-b receptor type II (TbRII), followed by the transphosphorylation of the TGF-b receptor type I (TbRI), and the subsequent activation of downstream signaling molecules including Smad2, Smad3 and Smad4 (Shi and Massague, 2003) . TGF-b receptor type III (TbRIII) expression is specifically important for TGF-b2 signaling. Proposed mechanisms for resistance to TGF-b include decreased expression of TbRI, TbRII or TbRIII on the cell surface of melanoma, pancreas, breast and colon cancers (Schmid et al., 1995; Goggins et al., 1998; Grady et al., 1999; Calin et al., 2000; Buck et al., 2004) . Most epithelial-derived tumors (>85% of all human cancers) become resistant to the growth-inhibitory effect of TGF-b by different mechanisms (Pasche, 2001; Elliott and Blobe, 2005) . However, both the loss and elevation of TbRII expressions are associated with prostate cancer (Kim et al., 1996 (Kim et al., , 1998 Gerdes et al., 1998; Royuela et al., 1998) . The consequence of TGF-b signaling in the prostatic stromal cells in man has not been studied.
As many Wnt ligands are stromally secreted with cognate receptors expressed by the epithelia, Wnt proteins are good candidates for mediating stromalepithelial interactions. Nineteen closely related but distinct Wnt ligands are reported to date. In vertebrates, Wnt signaling can involve canonical and/or noncanonical pathways (Clevers, 2006; Johnson and Rajamannan, 2006) . The canonical or b-catenin-dependent pathway, rely on specific Wnt ligands to bind a transmembrane receptor complex for cytoplasmic accumulation of b-catenin, and eventual nuclear translocation with lymphoid enhancer binding factor 1/ T-cell-specific factor transcription factors (LEF1/TCF). Mutations in the canonical Wnt signaling pathway components, such as APC and b-catenin, are common in carcinoma of the colon, but are relatively rare in prostate cancer (Voeller et al., 1998; Morin, 1999 ). Yet, nuclear b-catenin accumulation in prostate cancer specimens is comparatively frequent (Morin, 1999; Chesire et al., 2002; Chen et al., 2004; Yardy and Brewster, 2005; Verras and Sun, 2006) . The report of epithelial expression of Wnt/b-catenin target gene, Twist, in 90% of human prostate cancer tissues further suggests the role of deregulated Wnt signaling pathway (Kwok et al., 2005 (Kwok et al., , 2007 . Thus, other mechanisms, besides mutations, need to be considered to explain the pervasive b-catenin/TCF activity documented in human prostate cancer.
This study was designed to address the role of stromal TbRII in prostatic tumorigenesis. The mouse with conditional knockout for TbRII in the stromal compartment (Tgfbr2 fspKO ) was previously reported to develop PIN (Bhowmick et al., 2004a) . Here, we report that the Tgfbr2 fspKO mouse prostates can in fact progress to adenocarcinoma. Stromal cells deficient in TGF-b responsiveness were further found to promote tumorigenesis in a Wnt3a-dependent manner. Finally, the loss of TbRII expression in stromal cells was recapitulated in human prostate cancer, in contrast to stromal cells associated with benign prostate epithelia.
Results
The loss of TbRII expression in the prostate stroma leads to adenocarcinoma The Tgfbr2 fspKO mouse model was used to study the contribution of the loss of TbRII in the prostatic stroma to prostatic adenocarcinoma progression. The Tgfbr2 fspKO mouse prostates develop PIN lesions by 6 weeks of age with 100% penetrance, as previously reported ( Figure 1a ) (Bhowmick et al., 2004a) . Electron microscopy further supported the failure of epithelial differentiation, as there were no secretory vesicles in the 6-to --7-week-old Tgfbr2 fspKO mouse prostate epithelial cells, compared with their presence in Tgfbr2 floxE2/floxE2 (floxed TGF-b type II receptor) mouse prostates (Figure 1b) . If PIN is assumed to be a precursor of prostate adenocarcinoma, the progression of the disease was predicted in under long-term observation (Davidson et al., 1995; Qian et al., 1995) . As the Tgfbr2 fspKO mice die by 7 weeks of age, the prostates were rescued at 6 weeks and allografted to the renal capsule of immunocompromised male SCID mice. Twenty five percent of the Tgfbr2 fspKO prostates developed into adenocarcinoma by 7 months following grafting (Figure 1c ). Tissuerescued prostates from 6-week-old Tgfbr2 floxE2/floxE2 mice under the same conditions were histologically normal by hematoxylin and eosin (H&E) staining. Immunohistochemistry for the expression of TbRII confirmed a significant decrease in TbRII expression in the stromal compartment of Tgfbr2 fspKO prostates (Figure 1d ). Epithelial proliferation and differentiation markers were used to evaluate the development of prostate adenocarcinoma. The mitotic rate of the prostatic epithelium of Tgfbr2 fspKO mice was four-fold greater than that from Tgfbr2 floxE2/floxE2 mice in the 7-month progression model, as determined by quantitating phosphorylated-histone H3 expression (Figure 2a ). The mouse dorsolateral prostate (MDLP) antibody used to localize secretions found in differentiated prostatic epithelium was present in the Tgfbr2 floxE2/floxE2 tissues but was focally absent in Tgfbr2 fspKO tissues (Figure 2b ) (Donjacour et al., 1990) . Then MDLP staining in both normal and malignant rescued tissues confirmed the prostatic origin of the tissues. P63 expression was basally localized in the Tgfbr2 floxE2/floxE2 tissues, as expected ( Figure 2c ) (Kurita et al., 2004) . In contrast, p63-positive cells were rare and scattered in the Tgfbr2 fspKO prostate rescues, supportive of the progression of adenocarcinoma and indicating a disruption of the basal cell layer. Another reported marker for prostatic adenocarcinoma progression, Twist, was detected only in the Tgfbr2 fspKO tissue rescues that progressed to adenocarcinoma (Figure 2d ) (Kwok et al., 2005; Hotz et al., 2007; Zhang et al., 2007) . The loss of TbRII expression in the stroma resulted in the progression of prostate tumorigenesis in mice. (Figure 3b ). This indicated TGF-b signaling as a suppressor of Wnt3a expression in prostate stromal cells and potential paracrine mediator prostate epithelial Wnt signaling.
To test the specific role of Wnt3a on epithelial transformation and proliferation, LNCaP cells were incubated with conditioned media from either Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO mouse prostatic stromal cells in the presence or absence of a Wnt3a neutralizing antibody. The transcriptional activity of a canonical Wnt oncogenic target, c-myc, was measured by a luciferase reporter assay. The LNCaP cells incubated with Tgfbr2 fspKO conditioned media consistently had three-fold greater c-myc reporter activity than those cells incubated with Tgfbr2 floxE2/floxE2 conditioned media (Figure 4a ). Under the same conditions, the addition of the Wnt3a neutralizing antibody downregulated reporter activity of the LNCaP cells incubated with Tgfbr2 fspKO conditioned media to levels similar to that found when associated with Tgfbr2 floxE2/floxE2 conditioned media alone. Further, Tgfbr2 fspKO conditioned media induced 2.7-fold increase in proliferation of LNCaP cells relative to Tgfbr2 floxE2/floxE2 conditioned media ( Figure 4b ). Wnt3a neutralizing antibody reduced the proliferative effect of Tgfbr2 fspKO conditioned medium in a dosedependent manner. The presence of 10 ng/ml Wnt3a neutralizing antibody decreased LNCaP cell proliferation to comparable levels as cells grown in Tgfbr2 floxE2/floxE2 conditioned medium.
Next, the mechanism of transcriptional upregulation of Wnt3a in the Tgfbr2 fspKO prostatic stromal cells was analysed. A transcription factor-binding site search 5 kb upstream of the Wnt3a transcription start site suggested putative Stat DNA-binding elements at À863/À854 bp and À3551/À3542 bp (http://www.cbrc.jp/research/db/ TFSEARCH.html, http://genome-www.stanford.edu/ cgi-bin/genecards/carddisp.pl?gene ¼ Wnt3a, http://www. cbil.upenn.edu/cgi-bin/tess/tess). Chromatin immunoprecipitation (ChIP) analysis indicated that in vivo, the À854 bp consensus site had elevated Stat3 binding in Tgfbr2 fspKO prostate stromal cells compared to Tgfbr2 floxE2/floxE2 stroma. However, the À3542 bp consensus site was specifically occupied by Stat3 in Tgfbr2 fspKO prostatic stromal cells but not detectible in the Tgfbr2 floxE2/floxE2 prostatic stromal cells (n ¼ 4, Figure 4c ). Accordingly, we focused on the role of Stat3 on Wnt3a expression in Tgfbr2 fspKO prostate stromal cells. Western blotting resolved reduced Wnt3a expression when Stat3 was knocked down by small interfering RNA (siRNA) compared to scrambled siRNA control ( Figure 4d ). Together, the data indicate stromal TGF-b responsiveness regulates Wnt3a expression in a Stat3-dependant mechanism to induce Wnt activity in adjacent epithelial cells.
Tgfbr2
fspKO prostatic stromal cells promote human prostate cancer progression To determine whether the tumorigenic effects of the prostatic stroma were a result of paracrine signaling, tissue recombination techniques were used to combine cultured Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO prostatic stromal cells with adult wild-type mouse prostatic epithelial organoids. Following allografting the tissue recombinants into syngenic C57BL/6 male mice for 8 weeks, we found that the Tgfbr2 floxE2/floxE2 stroma-associated prostatic grafts were comparable to intact prostates of wildtype mice. The Tgfbr2 fspKO stroma-associated prostatic grafts developed PIN lesions, recapitulating the intact Tgfbr2 fspKO prostates (Figure 5a ). These results revealed that paracrine factors affected prostatic epithelial differentiation and established the tissue recombination methodology as a viable model for subsequent grafting experiments. To enable the study of stromal-epithelial signaling in adenocarcinoma, we developed a chimeric model of mouse prostatic stromal cells with LNCaP cells, an established human prostate cancer epithelial line. A five-fold increase in gross tumor volumes was observed in recombinants of LNCaP/Tgfbr2 fspKO compared to tumors of LNCaP/Tgfbr2 floxE2/floxE2 recombinants (Figure 5b ). Although the histology of the two chimeric tissues was not appreciably different (Figure 5c ), immunohistochemistry of phosphorylatedhistone H3 revealed increased mitosis in LNCaP/ Tgfbr2 fspKO tissue recombinants compared to LNCaP/ Tgfbr2 floxE2/floxE2 recombinants ( Figure 5d ). Together, the loss of TbRII expression in the stroma initiated paracrine transformation of normal epithelia and supported tumor progression of prostate cancer.
Next, host mice harboring the chimeric LNCaP/ Tgfbr2 fspKO tissue recombinants were treated with the Wnt3a neutralizing antibody or isotype IgG control. The antibodies were injected intraperitoneally 2 weeks following xenografting. Although the gross tumor size between the isotype IgG control and the Wnt3a neutralizing antibody were not appreciably different, the histology of the tumors revealed areas of necrosis in the tumors when mice were treated with the neutralizing antibody compared to control (Figure 6a ). Further immunolocalization for cells under going apoptosis confirmed 2.3-fold greater number in tumors treated prostates, yet only epithelial staining in the Tgfbr2 fspKO prostates. Scale bar represents 50 mm for panels a, c and d; 25 mm for insets.
Paracrine Wnt3a signaling in prostate cancer X Li et al with the Wnt3a neutralizing antibody compared to the control (P-value ¼ 0.001, Figure 6b ). There was a lack of mitotic cells in the areas of necrosis, as determined by phosphorylated-histone 3 immunolocalization (Figure 6b ).
The mitotic rate in the surviving tumors from neutralizing antibody-treated mice was significantly less than that in isotype control mice (P-value ¼ 0.002, Figure 6c ). Thus, downregulation of TGF-b signaling in the prostatic stromal compartments is associated with canonical Wnt signaling in the adjacent epithelia to support tumor initiation and further tumor progression. Inhibiting paracrine Wnt3a activity was effective in reducing growth of tumors deficient in stromal TGF-b signaling.
TbRII expression is lost in stromal cells of human prostate adenocarcinomas Finally, to explore the role of stromal TGF-b signaling in human prostate cancer progression, we localized TbRII expression by immunohistochemistry of 140 benign and malignant prostate tissues. Prostate samples from patients who underwent radical prostatectomy were obtained from Vanderbilt University and Imgenex Co. These patients received no documented treatment before surgery. The tissues were grouped based on Gleason score, and compared based on the staining for TbRII in the prostatic stroma (Figure 7) . The TbRII antibodies that tested in the respective Tgfbr2 floxE2/floxE2
and Tgfbr2 fspKO prostates ( Figure 1d ) were used for these immunohistochemical studies. TbRII was highly expressed in epithelial cells of all prostate samples examined. The stromal TbRII staining pattern, although less intense, was representative of >95% of the tissue in each array spot based on blinded pathology scoring (Figure 7) . Stromal TbRII was expressed in 85% of the tissues associated with benign epithelia. In contrast, an average 31% of the prostate cancer tissues with Gleason scores 6-10 maintained stromal TbRII staining. Further the clinical correlates, presurgical serum prostatespecific antigen expression and age (P-value ¼ 0.97, 0.31, respectively), did not statistically distinguish between benign and prostate cancer in this population. There was no correlation of stromal TGF-b expression and a specific Gleason score. As the proportions of stromal TGF-b expression for malignant samples were relatively similar to each other than that of benign samples, counts in malignant samples were combined and compared to the benign group. Multivariant analysis suggested the odds of positive stromal TbRII is 11.5 times as high in the benign group compared to the malignant group (with 95% power; confidence interval: 4.2-31.3; P-value o0.0001).
Discussion
The progression of the grafted prostate tissue rescues from Tgfbr2 fspKO mouse to adenocarcinoma led us to focus on the consequence of the loss of TGF-b signaling in the stroma on malignant progression. Although PIN lesions spontaneously developed in the Tgfbr2 fspKO mouse prostates by 5-7 weeks of age, it was not clear whether the model supported further progression to adenocarcinoma (Bhowmick et al., 2004a) . Owing to early lethality of the Tgfbr2 fspKO mice, we used tissue rescue and recombination grafting techniques to reveal the long-term role of stromal TGF-b signaling in tumor prostates. The sections were nuclear counterstained with hematoxylin (blue). Scale bar represents 50 mm for panels and 25 mm for insets.
Paracrine Wnt3a signaling in prostate cancer X Li et al progression. As only 25% of the Tgfbr2 fspKO mouse prostates progressed to adenocarcinoma, we chose to use an established human prostate cancer cell line, LNCaP, to further study the paracrine impact of the loss of TGF-b responsiveness in the stroma. LNCaP cells do not express functional TGF-b receptors (Guo and Kyprianou, 1999) . Thus, the resulting differences in the tumor size between Tgfbr2 floxE2/floxE2 and Tgfbr2 fspKO prostatic stroma-associated tissue recombinants ( Figure 5 ) were due to TGF-b signaling differences in the tumor microenvironment. It is likely that stromally derived factors normally suppressed by TGF-b signaling accelerated LNCaP tumor progression. A candidate approach identified Wnt3a as one such TGF-b-regulated cytokine, subsequently was shown to have an important role in tumor survival. Elevated Wnt signaling is attributed in the initiation and progression of prostate cancer with relatively infrequent mutations in the pathway (Yardy and Brewster, 2005) . This study provides a mechanism for the elevated Wnt activity in prostate epithelia. The loss of TbRII expression in the stroma of 69% of human prostatic cancer tissues and the resulting signaling repercussions suggests that the relatively frequent evidence of elevated Wnt signaling in prostate cancer can be a result of paracrine activity. The data further support stromal TGF-b signaling to be a tumor suppressor in the prostate (Bhowmick et al., 2004b; Bhowmick and Moses, 2005) .
The expression of TbRII in mature prostate epithelial cells is thought to contribute to the relatively low proliferative state. Accordingly, previous studies hypothesized that a loss of epithelial TbRII expression had a role in the process of high-grade prostate cancer progression. However, immunohistochemical staining for TbRII expression are ambiguous with reports of both decreased and elevated TbRII expression in prostate adenocarcinomas (Kim et al., 1996 (Kim et al., , 1998 Gerdes et al., 1998; Royuela et al., 1998; Cardillo et al., 2000) . Our focus was on stromal TbRII expression in prostate cancer progression. We do not make any Figure 7 ). Stromal staining associated with PIN lesions in the human tissues were not examined, as it was impossible to determine which lesions would progress to cancer. The question of TbRII antibody specificity in our immunohistochemistry study was addressed by the positive and negative stromal staining pattern in the Figure 6 Wnt3a neutralizing antibody inhibits tumorigenic progression of LNCaP/Tgfbr2 fspKO tissue recombinants. Wnt3a neutralizing antibody or isotype control IgG was intraperitoneally. injected to the hosted SCID mice twice a week for 2 weeks, started 2 weeks post-grafting. We report on TGF-b regulation of paracrine Wnt signaling, rather than the better-studied intracellular interaction between the TGF-b and Wnt signaling pathways. Incidentally, many Wnt ligands are stromally secreted with cognate receptors expressed by the epithelia, such as human prostate cancer tissues (Ellwood-Yen et al., 2003; Kwok et al., 2005) . Wnt target genes, such as Twist (Figure 2 ) and c-myc (Figure 4) , were upregulated in the epithelium associated with Tgfbr2 fspKO prostate stroma (Bhowmick et al., 2004a) . In a comparison of primary cultured prostatic stromal cells from Tgfbr2 floxE2/floxE2 and Tgfbr2 fspKO mice, we found that the expression of Wnt ligands were upregulated in Tgfbr2 fspKO stromal cells (Figure 3 ). There was a pronounced upregulation of Wnt3a at both RNA and protein levels. Ectopic expression has shown that Wnt3a to be a secreted form of Wnt ligand, unlike other Wnt proteins that associate with the cell membrane (Shibamoto et al., 1998) . Although no Smadbinding elements were found in the Wnt3a gene promoter, Stat-binding sites were predicted. Interestingly, TGF-b signaling is reported to inhibit Stat3 in T lymphocytes (Bright and Sriram, 1998) and corroborated here in the prostate stroma. We showed that the knockout of TGF-b signaling in prostate stromal fibroblasts resulted in the upregulation of Stat3 binding of the Wnt3a promoter by ChIP analysis (Figure 4) . The neutralization of Wnt3a in Tgfbr2 fspKO stromal conditioned media reduced LNCaP proliferation in vitro. The neutralization of Wnt3a in mice with LNCaP tumor xenografts also resulted in greater areas of cell death due to necrosis and apoptosis in LNCaP tumors, accompanied by lower rate of mitosis compared to those treated with the IgG isotype control (Figure 6 ). The mechanism for the TGF-b paracrine cross talk with Wnt signaling seems to be mediated in part through Stat3 signaling. Paracrine Wnt3a signaling in prostate cancer X Li et al Previously, we reported that paracrine hepatocyte growth factor signaling is involved in the tumorigenesis observed in Tgfbr2 fspKO mice. Here, the data suggest that disruption of TGF-b signaling in the prostatic stromal cells upregulates the expression of Wnt3a to promote tumorigenesis in a Stat3-dependent manner. Clearly, tumor initiation and progression is not a single signaling pathway event. Interestingly, the induction of hepatocyte growth factor and Wnt3a, resulting from the disruption of stromal Tgfbr2, is tied by elevated activation of Stat3. We showed in this study the increased Stat3 binding with Wnt3a promoter activity. Stat3 activation can also induce hepatocyte growth factor expression by co-operation with Src (Qiao et al., 2002; Wojcik et al., 2006; Sam et al., 2007) . In the context of a tumor many growth factors, including interleukin-6, hepatocyte growth factor and insulin-like growth factor-1, are known stimulators of Stat proteins. Thus, there are multiple potential mechanisms that would support paracrine Wnt3a signaling in prostate cancer. Similar to other targeted monoclonal antibodybased therapies in the clinic, the Wnt3a neutralizing antibody was well tolerated by the host mice. This is the first attempt of using Wnt3a neutralizing antibody to inhibit prostate tumor growth. The promising outcome suggests that such Wnt antagonists can be effective for prostate cancer patients, specifically those with undetectable stromal TbRII expression.
Materials and methods

Animals
Tgfbr2
floxE2/floxE2 and Tgfbr2 fspKO mice bred on the C57BL/6 background were generated and maintained as previously described (Bhowmick et al., 2004a) . Adult male severe combined immunodeficient (SCID) mice and C57BL/6 mice were purchased from Harlan (Indianapolis, IN, USA). Vanderbilt Institutional Animal Care and Use Committee approved the animal procedures.
Cell culture and production of conditioned medium Primary mouse prostate stromal cell cultures were generated from 6-to 8-week-old Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO mice. Briefly, the prostates were dissected, cut into 2 mm 3 pieces, plated on 6-well plates in high glucose Dulbecco's Modified Eagle's Medium, supplemented with 10% fetal bovine serum, 10 À8 M testosterone and 5 mg/ml insulin (Sigma-Aldrich, St Louis, MO, USA). Once the cells reached confluence, they were subcultured up to five passages and then discarded. LNCaP cells were purchased from ATCC, routinely passaged in RPMI medium containing 10% fetal bovine serum and 0.1% penicillin/streptomycin. Conditioned Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO stromal media were collected after two passages, from approximately 1 Â 10 6 cells plated on a 100 mm dish for 3 days in culture media and centrifuged before application on LNCaP cells. The conditioned media was normalized by the cell numbers at the time of collection.
Tissue rescue and tissue recombination Tissue rescues were performed by direct grafting of prostates dissected from 6-week-old Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO mice into the renal capsule of SCID mice, as previously described (Wang et al., 2000) . The rescued tissues were harvested after 7 months. Prostate tissue recombinants were generated by combining 250,000 Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO prostatic stromal cells with either prostate epithelial organoids from wild-type mice, or 100 000 cultured LNCaP cells, in 50 ml of rat-tail collagen. The prostate epithelial organoids were obtained from C57BL/6 mice (8-12 weeks) by collagenase digestion as previously reported (Turner et al., 1990; Hayward et al., 1992) . The tissue recombinants were grafted under the renal capsule of C57BL/6 mice (for recombinants of prostate organoids) or SCID mice (for LNCaP cell recombinants) (Fujii et al., 1982; Wong et al., 1992; Cunha, 1994; Hayward et al., 2001) . Host mice were killed 2 months or 7 weeks following grafting. The grafts were removed, photographed and processed for histologic evaluation. The dimensions were measured, and the tumor volume was calculated by the formula: volume ¼ width Â length Â 0.52 using Image J program. Note that the formula underestimates the volume of invasive tumors, and accordingly underestimate the significance of size differences between small noninvasive and larger invasive tumors.
Measurement of cell proliferation and luciferase assay
The LNCaP cells were passaged at 1 Â 10 5 cells per well in 24-well plates. After overnight growth and attachment, the culture media were changed to either Tgfbr2 floxE2/floxE2 or Tgfbr2 fspKO stromal conditioned media. The cells in Tgfbr2 fspKO stromal condition medium were treated with or without Wnt3a neutralization antibody at 1-15 ng/ml, final concentration. Cell numbers were counted by hemocytometer after 72 h.
The cells passaged in the 24-well plates were otherwise transfected with c-myc luciferase construct (He et al., 1998) with Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA), according to the users' manual. Next day the cells were treated with conditioned media with/without Wnt3a neutralizing antibody, or control rat IgG for 24hrs before the cells were harvested, analysed using Luciferase assay system (Promega, Madison, WI, USA), normalized by total protein content.
Antibodies and immunohistochemistry
Paraffin-embedded tissue sections (5 mm) were deparaffinized and hydrated through xylene and graded alcohols using a standard protocol. A voulume of 1% antigen unmasking solution (Vector laboratories, Burlington, CA, USA) was used for antigen retrieval, according to the manufacturer's instructions. Subsequent immunohistochemical staining used antibodies against phosphorylated-histone H3 (1:1000, Upstate, Temecula, CA, USA), TGFb type II receptor or p63 (1:1000, Santa Cruz Biotech, Santa Cruz, CA, USA) and Twist (1:500, Santa Cruz). Appropriate HRP-conjugated secondary antibodies and DAB incubation (Dako North America, Carpinteria, CA, USA) were used for visualization. The ApopTag peroxidase in situ apoptosis detection kit (Chemicon, Temecula, CA, USA) was used to detect apoptotic cells, according to the manufacturer's instructions.
The host SCID mice grafted with prostate tissue recombinants were injected intraperitoneally with mouse monoclonal Wnt3a or isotype control IgG (R&D Systems, Minneapolis, MN, USA), at 100 mg per mouse in a 0.2 ml volume. Injection was started 2 weeks after grafting and subsequently twice weekly until killed on the fourth week post-grafting.
siRNA transfection and western analysis Primary cultured mouse prostate stromal cells were transfected with Stat3 siRNA or the control siRNA using siRNA transfection reagent (Santa Cruz Biotech), the cells were harvested after 48 h. Samples were separated by 10% SDSpolyacrylamide gel electrophoresis gel and electrotransferred to nitrocellulose membrane. Membranes were blocked and incubated with primary antibodies for Wnt3a (R&D systems) or anti-actin (Santa Cruz) overnight at 4 1C. Respective horseradish peroxidase conjugated secondary antibodies (GE Healthcare, Piscataway, NJ, USA) were applied to the blots for 1 h. Protein bands were visualized using ECL plus western blotting detection system (GE Healthcare).
Real-time quantitative reverse transcription-PCR and ChIP analysis RNA was extracted using the RNAeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Reverse transcription and quantitative real-time PCR used iScript and iQ SYBR Green supermix, respectively (Bio-Rad, Hercules, CA, USA). Relative quantitation was calculated by DDC t method normalized to 18 s rRNA. See supplementary Information for sequences of reverse transcription-PCR primers.
Tgfbr2 floxE2/floxE2 and Tgfbr2 fspKO prostate stromal cells were grown to confluence before crosslinked with 1% formaldehyde, lysed and sonicated as described previously (Nissen and Yamamoto, 2000) . Chromatin fragments were immunoprecipitated with Stat3 antibody and normal mouse IgG as negative control (Santa Cruz Biotech) overnight at 4 1C. After immunoprecipitation, 60 ml protein-G Agarose were added to pull down the chromatin/protein-antibody complex, and further steps following the protocol from the EZ Chip kit (Upstate). The PCRs were performed for 30 cycles with the primers: forward-TGGACTCAGGAGGAATCAATGTGG and reverse-CGAGGTAGTTGTTAGGGAGTCCAA for the À854 Stat3-binding site of Wnt3a promoter and forward-AGAGGG ACCCATTCCTCTGTGAAA and reverse-TGGAGCTGGA ACTCAAGGAACTGT for the À3542 Stat3-binding site of Wnt3a promoter. PCR products were resolved on a 1.5% agarose gel and visualized with ethidium bromide.
Human prostate tumor samples and tissue microarray Human prostate samples were collected from radical prostatectomy tissue, with prostate cancer and adjacent normal areas indicated by a pathologist consistent with Institutional Review Board approval. The tissues were evaluated following 4% paraformaldehyde fixation, paraffin embedding and H&E staining of 5 mm sections. Fifteen such benign prostate samples in addition to the samples from tissue microarray (TMA, Imgenex, San Diego, CA, USA) that included 125 tissue cores with benign and cancer histology were immunohistochemically stained. Information on all tissue samples including Gleason score, prostate-specific antigen expression, clinical stage and H&E were available.
Statistical analysis
The univariant associations between the clinical correlates and the stromal TGF-b were tested using Wilcoxon rank-sum tests. To express the relationship between the proportions of stromal TGF-b and Gleason scores, log-linear models were considered. Odds of TGF-b expression were computed for benign and malignant samples, and the results were reported in terms of the odds ratio. All reported P-values were two-sided. 
